ReproCELL Incorporated

TSE:4978 Stock Report

Market Cap: JP¥16.1b

ReproCELL Past Earnings Performance

Past criteria checks 3/6

ReproCELL has been growing earnings at an average annual rate of 44.9%, while the Biotechs industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 17.2% per year. ReproCELL's return on equity is 1.1%, and it has net margins of 3.5%.

Key information

44.91%

Earnings growth rate

48.28%

EPS growth rate

Biotechs Industry Growth31.91%
Revenue growth rate17.18%
Return on equity1.15%
Net Margin3.46%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

May 15
Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

The Market Doesn't Like What It Sees From ReproCELL Incorporated's (TSE:4978) Revenues Yet As Shares Tumble 28%

Apr 07
The Market Doesn't Like What It Sees From ReproCELL Incorporated's (TSE:4978) Revenues Yet As Shares Tumble 28%

ReproCELL Incorporated's (TSE:4978) Price Is Right But Growth Is Lacking

Jan 28
ReproCELL Incorporated's (TSE:4978) Price Is Right But Growth Is Lacking

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Aug 05
ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17
Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Feb 07
Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Revenue & Expenses Breakdown

How ReproCELL makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4978 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 252,9781031,243536
31 Dec 242,718-1101,217484
30 Sep 242,599-1951,177453
30 Jun 242,489-1781,187418
31 Mar 242,426-311,131384
31 Dec 232,506-2181,088429
30 Sep 232,524-3131,057459
30 Jun 232,843-2751,010481
31 Mar 232,953-305984501
31 Dec 222,969-263936468
30 Sep 222,821-306927466
30 Jun 222,518-411893466
31 Mar 222,234-575898535
31 Dec 211,825-505898571
30 Sep 211,661-648875642
30 Jun 211,500-726884713
31 Mar 211,286-812843662
31 Dec 201,257-1,011883626
30 Sep 201,249-945859558
30 Jun 201,111-995859482
31 Mar 201,199-1,016889454
31 Dec 191,173-834886388
30 Sep 191,114-809943317
30 Jun 191,090-750964282
31 Mar 191,088-601971273
31 Dec 181,046-1,950805277
30 Sep 181,018-1,965846264
30 Jun 18969-2,052908233
31 Mar 18926-2,172982191
31 Dec 171,083-1,0191,122203
30 Sep 171,187-7591,071237
30 Jun 171,202-7651,031256
31 Mar 171,257-9111,011276
31 Dec 161,136-1,838882277
30 Sep 161,043-2,150958274
30 Jun 161,069-2,199984282
31 Mar 161,066-1,961979289
31 Dec 151,023-7911,218337
30 Sep 15917-7201,111340
30 Jun 15743-518947316
31 Mar 15567-451736280
31 Dec 14473-359487186
30 Sep 14463-187345147
30 Jun 14462-140268133

Quality Earnings: 4978 has high quality earnings.

Growing Profit Margin: 4978 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4978 has become profitable over the past 5 years, growing earnings by 44.9% per year.

Accelerating Growth: 4978 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 4978 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.2%).

Return on Equity

High ROE: 4978's Return on Equity (1.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 08:20
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ReproCELL Incorporated is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Akinori UedaGoldman Sachs